Mettez-vous hors ligne avec l'application Player FM !
3/30/2022 - COVID-19 BA.2 Subvariant & Boosters
Manage episode 324232432 series 2065653
Dr. Paul Auwaerter discusses the BA.2 Subvariant and the recent authorization from the FDA for second booster dose. Topics: *Virulence of BA.2 vs Omicron and Delta * Therapeutic activity of monoclonal antibodies against BA.2 *Details of approval for booster #2 (4th and 5th dose) *Are there advantages to mixing mRNA vaccines?
Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/3-30-22-episode/eval
Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty
Presenting faculty:
Paul G. Auwaerter, MD, MBA, FIDSA, Past President of the Infectious Diseases Society of America (IDSA), Professor of Medicine, Johns Hopkins University School of Medicine
Hosted on Acast. See acast.com/privacy for more information.
214 episodes
Manage episode 324232432 series 2065653
Dr. Paul Auwaerter discusses the BA.2 Subvariant and the recent authorization from the FDA for second booster dose. Topics: *Virulence of BA.2 vs Omicron and Delta * Therapeutic activity of monoclonal antibodies against BA.2 *Details of approval for booster #2 (4th and 5th dose) *Are there advantages to mixing mRNA vaccines?
Post-test for CME/CE credit: https://covid19.dkbmed.com/multispecialty/3-30-22-episode/eval
Access our resource center, download webinar slides, and claim credit at https://covid19.dkbmed.com/multispecialty
Presenting faculty:
Paul G. Auwaerter, MD, MBA, FIDSA, Past President of the Infectious Diseases Society of America (IDSA), Professor of Medicine, Johns Hopkins University School of Medicine
Hosted on Acast. See acast.com/privacy for more information.
214 episodes
Tous les épisodes
×Bienvenue sur Lecteur FM!
Lecteur FM recherche sur Internet des podcasts de haute qualité que vous pourrez apprécier dès maintenant. C'est la meilleure application de podcast et fonctionne sur Android, iPhone et le Web. Inscrivez-vous pour synchroniser les abonnements sur tous les appareils.